Commentary

The Year in Review, A Look Ahead

Overall, 2014 was an exciting year in interventional cardiology. We saw the presentation and publication of important trials as well as a number of new developments and approvals, such as the CoreValve transcatheter aortic valve replacement system (Medtronic) and the Lutonix drug-coated balloon (C.R. Bard) for the treatment of peripheral artery disease.

Each year, the Cardiology Today’s Intervention Editorial Board selects the Top 5 Trends for the upcoming year. Read more about their 2015 selections on page 9.

Topping this year’s list are new advances in TAVR. Technologies available in the United States and outside this country are changing rapidly. I am particularly excited about research on TAVR for the treatment of bicuspid aortic valves and select patients with aortic regurgitation. The valve-in-valve data are impressive. The ability to retrieve and reposition valves should also be a major advance. In terms of new valves, we are already seeing third-generation devices such as the Sapien 3 (Edwards Lifesciences) and the next-generation CoreValve.

Following presentation of the DAPT trial at the American Heart Association Scientific Sessions in November and other studies, questions remain regarding the optimal duration of dual antiplatelet therapy, which was ranked as No. 2 on the Top 5 Trends list. I look forward to results of the PEGASUS trial, which will compare ticagrelor (Brilinta, AstraZeneca) vs. placebo on top of aspirin in post-MI patients, a proportion of whom will be patients treated by interventional cardiologists. This study should hopefully provide some answers regarding the optimal duration and flavor of DAPT.

On my personal list, in 2015 I also anticipate more news and developments on: the future of renal denervation after the SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint; growing interest of interventional cardiologist involvement in acute stroke treatment; pulmonary embolism intervention with catheter-based endovascular systems; drug-coated balloons for lower-extremity peripheral intervention; and the CardioMEMS device for interventional heart failure procedures.

We welcome you to share your thoughts on the Top 5 Trends in 2015 by emailing the editor at cardiology@healio.com.

Deepak L. Bhatt, MD, MPH

Chief Medical Editor, Cardiology Today’s Intervention

Overall, 2014 was an exciting year in interventional cardiology. We saw the presentation and publication of important trials as well as a number of new developments and approvals, such as the CoreValve transcatheter aortic valve replacement system (Medtronic) and the Lutonix drug-coated balloon (C.R. Bard) for the treatment of peripheral artery disease.

Each year, the Cardiology Today’s Intervention Editorial Board selects the Top 5 Trends for the upcoming year. Read more about their 2015 selections on page 9.

Topping this year’s list are new advances in TAVR. Technologies available in the United States and outside this country are changing rapidly. I am particularly excited about research on TAVR for the treatment of bicuspid aortic valves and select patients with aortic regurgitation. The valve-in-valve data are impressive. The ability to retrieve and reposition valves should also be a major advance. In terms of new valves, we are already seeing third-generation devices such as the Sapien 3 (Edwards Lifesciences) and the next-generation CoreValve.

Following presentation of the DAPT trial at the American Heart Association Scientific Sessions in November and other studies, questions remain regarding the optimal duration of dual antiplatelet therapy, which was ranked as No. 2 on the Top 5 Trends list. I look forward to results of the PEGASUS trial, which will compare ticagrelor (Brilinta, AstraZeneca) vs. placebo on top of aspirin in post-MI patients, a proportion of whom will be patients treated by interventional cardiologists. This study should hopefully provide some answers regarding the optimal duration and flavor of DAPT.

On my personal list, in 2015 I also anticipate more news and developments on: the future of renal denervation after the SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint; growing interest of interventional cardiologist involvement in acute stroke treatment; pulmonary embolism intervention with catheter-based endovascular systems; drug-coated balloons for lower-extremity peripheral intervention; and the CardioMEMS device for interventional heart failure procedures.

We welcome you to share your thoughts on the Top 5 Trends in 2015 by emailing the editor at cardiology@healio.com.

Deepak L. Bhatt, MD, MPH

Chief Medical Editor, Cardiology Today’s Intervention